The Pharmacology of Lysergic Acid Diethylamide: A Review
- T. Passie, J. Halpern, D. Stichtenoth, H. Emrich, A. Hintzen
- Psychology, MedicineCNS Neuroscience & Therapeutics
- 1 December 2008
There is new interest in LSD as an experimental tool for elucidating neural mechanisms of (states of) consciousness and there are recently discovered treatment options with LSD in cluster headache and with the terminally ill.
Hallucinogens and dissociative agents naturally growing in the United States.
- J. Halpern
- BiologyPharmacology and Therapeutics
- 1 May 2004
Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth).
The predominant alkaloid of kratom, mitragynine, binds mu- and kappa-opioid receptors, but has additional receptor affinities that might augment its effectiveness at mitigating opioid withdrawal.
Residual neuropsychological effects of illicit 3,4-methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs.
Hallucinogen persisting perception disorder: what do we know after 50 years?
Response of cluster headache to psilocybin and LSD
The authors interviewed 53 cluster headache patients who had used psilocybin or lysergic acid diethylamide (LSD) to treat their condition to find out whether these patients had aborted attacks or reported remission period extension.
Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament.
- J. Halpern, A. Sherwood, T. Passie, K. C. Blackwell, A. J. Ruttenber
- MedicineMedical Science Monitor
- 1 August 2008
For those who have religious need for ingesting ayahuasca, from a psychiatric and medical perspective, these pilot results substantiate some claims of benefit, especially if subjects interviewed fully reflect general membership.
Genuine and drug-induced synesthesia: A comparison
Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence.
- T. Passie, H. Emrich, M. Karst, S. Brandt, J. Halpern
- Psychology, BiologyDrug Testing and Analysis
- 1 July 2012
It is shown that recent studies provided supporting evidence that PTSD patients may be able to cope with their symptoms by using cannabis products and it is concluded that further studies are warranted in order to evaluate the therapeutic potential of cannabinoids in PTSD.
Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs.
Little evidence of decreased cognitive performance in ecstasy users, save for poorer strategic self-regulation, possibly reflecting increased impulsivity is found, emphasizing the need for continued caution in interpreting field studies of cognitive function in illicit ecstasy users.